Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) Net Margin: 2022-2025

Historic Net Margin for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to 0.22%.

  • Addex Therapeutics' Net Margin fell 1243538.00% to 0.22% in Q2 2025 from the same period last year, while for Jun 2025 it was 1.06%, marking a year-over-year decrease of 120663.00%. This contributed to the annual value of 1,746.04% for FY2024, which is 240051.00% up from last year.
  • Addex Therapeutics' Net Margin amounted to 0.22% in Q2 2025, which was down 88.26% from 1.88% recorded in Q1 2025.
  • Addex Therapeutics' Net Margin's 5-year high stood at 12,435.61% during Q2 2024, with a 5-year trough of -78,901.26% in Q4 2024.
  • Its 3-year average for Net Margin is -7,194.11%, with a median of -415.37% in 2023.
  • Data for Addex Therapeutics' Net Margin shows a peak YoY increase of 1,285,964bps (in 2024) and a maximum YoY decrease of 7,831,605bps (in 2024) over the last 5 years.
  • Addex Therapeutics' Net Margin (Quarterly) stood at 1,071.63% in 2022, then crashed by 165,684bps to -585.21% in 2023, then tumbled by 7,831,605bps to -78,901.26% in 2024, then crashed by 1,243,538bps to 0.22% in 2025.
  • Its last three reported values are 0.22% in Q2 2025, 1.88% for Q1 2025, and -78,901.26% during Q4 2024.